Cargando…
Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review
BACKGROUND: It has been shown that a subgroup of patients with differentiated thyroid cancer (DTC) and medullary thyroid carcinoma (MTC) would progress to advanced stages of thyroid cancer. Therefore, the present study was done to systematically review available evidence in order to investigate effi...
Autores principales: | Maghsoomi, Zohreh, Emami, Zahra, Malboosbaf, Ramin, Malek, Mojtaba, Khamseh, Mohammad E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139052/ https://www.ncbi.nlm.nih.gov/pubmed/34016077 http://dx.doi.org/10.1186/s12885-021-08257-x |
Ejemplares similares
-
Methadone‐induced hypoglycemia: A case report
por: Malboosbaf, Ramin, et al.
Publicado: (2022) -
Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer
por: Tumino, Dario, et al.
Publicado: (2017) -
Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer
por: Petranović Ovčariček, Petra, et al.
Publicado: (2023) -
Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls
por: Beukhof, Carolien M., et al.
Publicado: (2019) -
Advances in the Management of Medullary Thyroid Carcinoma: Focus on Peptide Receptor Radionuclide Therapy
por: Grossrubatscher, Erika, et al.
Publicado: (2020)